Pancreas & Biliary · Article 84

How Should Patients With Cirrhosis Be Screened for Esophageal Varices?

Variceal screening cirrhosis requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Variceal screening cirrhosis clinical reference — Related free clinical resource: Guideline-Based Management in Hepatology.

Variceal screening cirrhosis: practical clinical approach

This page focuses on Variceal screening cirrhosis with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Variceal screening cirrhosis

Clinical takeaway: For Variceal screening cirrhosis, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer in brief: Screening for varices is no longer synonymous with automatic EGD for every patient with cirrhosis. Current AASLD guidance uses noninvasive assessment of clinically significant portal hypertension (CSPH)—including liver stiffness, platelet count and imaging—to identify patients who may benefit from nonselective beta-blockers and those in whom screening EGD can be deferred. EGD remains important when noninvasive criteria are inconclusive or beta-blockers are contraindicated or not being used.

Key clinical points

Assess compensated cirrhosis for CSPH, not merely for the presence of varices.
Nonselective beta-blockers can prevent decompensation in patients with CSPH.
Some low-risk patients can avoid screening EGD using validated noninvasive criteria.
If beta-blockers cannot be used, EGD remains central for detecting varices needing prophylaxis.

Why the paradigm changed

Historically, EGD was performed in nearly every newly diagnosed cirrhosis patient to find varices. The 2024 AASLD guidance incorporates evidence that CSPH itself predicts decompensation and can often be assessed noninvasively.

Noninvasive assessment

Liver stiffness and platelet count, supplemented by imaging signs such as collaterals or splenomegaly, help determine the probability of CSPH. Very low-risk patients can defer endoscopy; high-risk patients may be candidates for carvedilol or another nonselective beta-blocker even before large varices are documented.

When EGD is still needed

Endoscopy remains appropriate when noninvasive tests do not confidently classify risk, when the patient cannot take nonselective beta-blockers, when bleeding risk needs direct assessment, or when there are other upper-GI indications.

If varices are found

Primary prophylaxis can involve nonselective beta-blockers or endoscopic variceal ligation depending on varix size, risk stigmata, blood pressure, comorbidities and patient preference. Management should be integrated with the broader cirrhosis plan.

Practical approach

1. Assess compensated cirrhosis for CSPH using noninvasive data.

2. Use NSBB therapy when appropriate to prevent decompensation/bleeding.

3. Perform EGD when beta-blockers are contraindicated or noninvasive risk remains uncertain.

4. Integrate variceal prophylaxis with overall cirrhosis management.

Common errors to avoid

Sending every compensated cirrhosis patient automatically to screening EGD without assessing CSPH.
Using endoscopic findings in isolation rather than integrating NSBB candidacy.

Trainee takeaway

Screening for varices is no longer synonymous with automatic EGD for every patient with cirrhosis. The examination question is usually less about memorizing one cutoff than recognizing which finding changes the next clinical decision.

Frequently asked questions

Does every patient with compensated cirrhosis need an EGD?

No. Current guidance allows selected low-risk patients to defer EGD based on noninvasive criteria.

Why use carvedilol before varices bleed?

In patients with CSPH, nonselective beta-blockade can reduce portal pressure and lower the risk of decompensation, not just variceal hemorrhage.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015. ISBN 978-1502928078.

2. Thomson ABR. Endoscopy and Diagnostic Imaging, Parts I–II. CAPstone Academic Publishers; 2012.

3. Kaplan DE, Ripoll C, Thiele M, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79:1180-1211. doi:10.1097/HEP.0000000000000647.

Editorial note: This educational article synthesizes Dr. Thomson’s teaching framework with current society guidance. Recommendations should be checked against the latest guideline, local formulary, regulatory labeling and the individual clinical context before patient-specific use.

← Back to Clinical Questions